Position in JSPR
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$256,894
-$279,344 QoQ
Shares Held
293,259
+0.1% QoQ
Ownership
1.05%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JSPR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026BANK OF AMERICA CORP /DE/ holds $8,555,077,811 across 347 Biotechnology names. JSPR ranks #282 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,878,183 | $1,285,223,834 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,189,584 | $919,120,177 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
966,912 | $319,922,169 | |
| 4 | ARGX |
Argenx SE
|
400,117 | $292,185,437 | |
| 5 | INSM |
INSMED Inc
|
1,502,281 | $245,652,986 | |
| 6 | CYTK |
Cytokinetics Inc
|
3,125,436 | $205,997,485 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
1,014,800 | $191,847,936 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
2,913,109 | $188,274,232 |
All Filings in JSPR
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $256,894 | 293,259 | Shares | Defined | 2026-05-18 | |
| 2025-12-31 | $536,238 | 293,027 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $701,035 | 294,553 | Shares | Defined | 2026-02-03 | |
| 2025-06-30 | $1,628,702 | 293,460 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $1,550,961 | 360,689 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $6,140,421 | 287,204 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $6,129,821 | 325,881 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $7,384,853 | 325,324 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $9,388,946 | 319,787 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||